Physicians' Academy for Cardiovascular Education

Healthy lifestyle after diabetes diagnosis reduces risk of CVD

Literature - July 3, 2018 - Liu G, et al. - J Am Coll Cardiol
Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.

Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.

Oral microsomal triglyceride transfer protein inhibitor is beneficial in HoFH

Literature - June 28, 2018 - Blom DJ, et al. - Orphanet J Rare Dis 2018
In patients with HoFH, lomitapide led to a significant reduction of LDL-c levels and to achievement of EAS targets in many patients, while CV event rates correlated with LDL-c levels.

In patients with HoFH, lomitapide led to a significant reduction of LDL-c levels and to achievement of EAS targets in many patients, while CV event rates correlated with LDL-c levels.

PCSK9 RNA silencing agent reduces LDL-c in diabetes patients with high CV risk

News - June 27, 2018

A subanalysis of the ORION-1 phase II trial showed that inclisiran reduced LDL-c in high CV risk patients, irrespective of presence of diabetes.

Mechanisms involved in HFpEF and how they are or may be targeted for therapy

Literature - June 26, 2018 - Lam CSP et al., - Eur Heart J 2018

This review describes six mechanisms underlying HFpEF with potential translational significance; three haemodynamic mechanisms and cellular/molecular mechanisms.

Trials with SGLT2 inhibitor in addition to insulin meet primary efficacy endpoint in type 1 diabetes patients

News - June 26, 2018

In two trials of the EASE phase III program, the primary endpoint of change in HbA1c after 26 week of empagliflozin in addition to insulin was met in type 1 diabetes patients.

Estimating CV risk and treatment benefit

Clinical updates in management of cardiovascular risk (4/4)

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands
Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

No increased risk of below-knee amputation with canagliflozin in real-world study

News - June 25, 2018

ADA 2018 In the OBSERVE-4D real world study, canagliflozin did not result in increased risk of below-knee amputation in T2DM patients or patients with established CVD.

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

People with ACS and diabetes particularly benefit from PCSK9 inhibitor and statin treatment

News - June 25, 2018

ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels

Comparison of GLP-1 receptor agonists shows variability in reductions of HbA1c and weight

News - June 25, 2018

In type 2 diabetes patients, semaglutide showed greater reductions of HbA1c and weight compared with liraglutide in the PIONEER 4 trial and compared with sitagliptin in the PIONEER 7 trial.

Cost-effective health benefits obtained with intense multifactorial treatment for T2DM

News - June 25, 2018

ADA 2018 In the long-term Danish Steno 2 study, interventions targeting complications were found to improve disease-free-life length, and costs were not higher than with conventional treatment.

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.

Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.